Hikma Pharmaceuticals PLC (Hikma), the multinational pharmaceutical company, today announces the launch of the first-of-its-kind, ready-to-use vancomycin premix with room-temperature stability under ...

Cevostamab demonstrated a 38.8% overall response rate in relapsed/refractory multiple myeloma, with a median response duration of 12.3 months. BCMA-naive patients showed a higher overall response rate ...

GC Biopharma (006280.KS), a leading global biopharmaceutical company, today announced the first shipment of BARYTHRAX inj., ...

The nonprofit operating the controversial facilities doesn't track outcomes for patients experiencing cardiac arrest, strokes ...

Treatment with intravenous (IV) iron significantly improved survival and increased hemoglobin levels in patients with ...

Comedian Park Na-rae, 40 years old, has faced allegations of receiving illegal medical treatments, following prior ...

Comedian Park Na-rae, who has faced allegations of power abuse against her manager and embezzlement suspicions, is now under scrutiny for allegedly receiving unauthorized medical treatment. The ...

Piperacillin and Tazobactam in the DUPLEX Drug Delivery System is one of many planned injectable drugs B. Braun will launch in the U.S. in the next several years to expand its portfolio and help meet ...

Sapu Nano today announced new pharmacokinetic (PK) and tissue-distribution results demonstrating that Sapu003, the company's intravenous (IV) Deciparticle(TM) formulation of everolimus, substantially ...

IV Sapu003 Reduces GI Exposure to Everolimus by 67-Fold Compared With Oral Dosing ...

If approved, ReadyFlow Autoinjector would deliver an IV-equivalent diuretic dose (subcutaneous furosemide injection 80 mg/ml) in under 10 ...

If approved, the new autoinjector formulation would allow patients to administer furosemide at home reducing administration time from 5 hours to under 10 seconds.